Press Release: ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
Sale of QVQ Holdings BV shares -- 121
-------------------------------------------- ------ ------
Net cash used in investing activities (328) (509)
-------------------------------------------- ------ ------
Financing activities:
Proceeds on share issuance, net of
transaction costs 1,507 --
Repayment of leases (801) (715)
Proceeds on debenture issuance, net
of transaction costs 4,059 --
---------------------------------------- ------ ------
Net cash provided by (used in) financing
activities 4,765 (715)
-------------------------------------------- ------ ------
Increase (decrease) in cash during the
period 370 (1,794)
Foreign exchange (294) (468)
Cash -- beginning of the period 3,545 8,366
-------------------------------------------- ------ ------
Cash -- end of the period 3,621 6,104
-------------------------------------------- ------ ------
Cash is comprised of:
Cash 3,534 6,017
Restricted cash 87 87
-------------------------------------------- ------ ------
3,621 6,104
---------------------------------------- ------ ------
Cash paid for interest -- --
Cash paid for income tax -- --
-------------------------------------------- ------ ------
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210683224/en/
CONTACT:
Investor Relations Contact
investors@ipatherapeutics.com
(END) Dow Jones Newswires
December 10, 2024 08:30 ET (13:30 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available